Why STAAR Surgical's Shares Are Gaining Today

  • The FDA approved STAAR Surgical Company's STAA EVO/EVO+ Visian Implantable Collamer Lens to correct myopia and myopia with astigmatism. Myopia, also known as nearsightedness or the need for distance vision correction.
  • The Company, in a statement, says that the EVO lens is additive, provides quality of vision day & night, does not cause dry eye syndrome, and, if required, can be removed by a doctor. 
  • EVO offers a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for distance vision correction. 
  • A U.S. multicenter, prospective clinical investigation confirmed the safety of the EVO family of myopia lenses. 
  • Read Next: BTIG Upgraded Staar Surgical Stock - Read Why.
  • More than 100 clinical papers are available discussing the safety and efficacy of the Visian ICL family of lenses globally.
  • Price Action: STAA shares are up 9.47% at $79.86 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsHealth CareFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!